Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Mol Diagn. 2006 May;6(3):277-86.

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

Author information

1
University of Kentucky, Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA. jdeleon@uky.edu

Abstract

The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

PMID:
16706732
DOI:
10.1586/14737159.6.3.277
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center